$DNLI
Denali Therapeutics Inc. Stock $dnli

$dnli Overview Financials Valuation SEC Filings Company Website

2021 Q4 Form 10-Q Financial Statement

#000171489921000106 Filed on November 04, 2021

Income Statement

Concept	2021 Q4	2021 Q3	2020 Q3
Revenue	$12.51M	$5.285M	$9.393M
YoY Change	-96.05%	-43.73%	-30.95%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$21.76M	$19.32M	$15.80M
YoY Change	20.88%	22.27%	41.07%
% of Gross Profit
Research & Development	$67.88M	$71.56M	$53.70M
YoY Change	24.09%	33.25%	2.21%
% of Gross Profit
Depreciation & Amortization	$2.094M	$2.187M	$2.100M
YoY Change	-0.29%	4.14%	10.53%
% of Gross Profit
Operating Expenses	$89.64M	$90.88M	$69.51M
YoY Change	23.29%	30.74%	9.02%
Operating Profit		-$85.59M	-$60.12M
YoY Change		42.38%	19.86%
Interest Expense	$1.285M	$1.005M	$1.900M
YoY Change	-19.69%	-47.11%	-50.0%
% of Operating Profit
Other Income/Expense, Net		$1.005M	$1.944M
YoY Change		-48.3%	-48.6%
Pretax Income	-$75.84M	-$84.59M	-$58.20M
YoY Change	-130.87%	45.34%	25.43%
Income Tax	-$575.0K	$0.00	$56.00K
% Of Pretax Income
Net Earnings	-$75.26M	-$84.59M	-$58.23M
YoY Change	-130.73%	45.27%	25.87%
Net Earnings / Revenue	-601.41%	-1600.53%	-619.91%
Basic Earnings Per Share		-$0.69	-$0.54
Diluted Earnings Per Share	-$616.0K	-$0.69	-$0.54
COMMON SHARES
Basic Shares Outstanding	122.1M shares	121.7M shares	107.5M shares
Diluted Shares Outstanding		121.7M shares	107.5M shares

Balance Sheet

Concept	2021 Q4	2021 Q3	2020 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$865.4M	$1.039B	$961.2M
YoY Change	-41.12%	8.11%	100.5%
Cash & Equivalents	$293.5M	$394.6M	$351.0M
Short-Term Investments	$571.9M	$644.6M	$610.2M
Other Short-Term Assets	$30.60M	$15.14M	$9.700M
YoY Change	50.74%	56.08%	-35.33%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$897.2M	$1.056B	$970.9M
YoY Change	-40.01%	8.72%	96.38%
LONG-TERM ASSETS
Property, Plant & Equipment	$38.87M	$40.01M	$42.27M
YoY Change	-4.85%	-5.33%	-10.99%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$425.4M	$319.5M	$20.30M
YoY Change	1201.07%	1473.75%	-13.62%
Other Assets	$11.87M	$3.777M	$3.858M
YoY Change	382.17%	-2.1%	19.0%
Total Long-Term Assets	$506.9M	$394.5M	$99.44M
YoY Change	366.68%	296.68%	-8.44%
TOTAL ASSETS
Total Short-Term Assets	$897.2M	$1.056B	$970.9M
Total Long-Term Assets	$506.9M	$394.5M	$99.44M
Total Assets	$1.404B	$1.450B	$1.070B
YoY Change	-12.47%	35.47%	77.5%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$4.779M	$4.817M	$2.806M
YoY Change	346.22%	71.67%	38.77%
Accrued Expenses	$53.17M	$44.67M	$11.53M
YoY Change	539.39%	287.41%	-25.45%
Deferred Revenue	$27.92M	$1.324M	$28.02M
YoY Change	40.18%	-95.27%	54.06%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$378.2M	$54.25M	$105.4M
YoY Change	427.55%	-48.53%	125.8%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$379.0K	$701.0K	$379.0K
YoY Change	-45.93%	84.96%	-1.81%
Total Long-Term Liabilities	$379.0K	$701.0K	$379.0K
YoY Change	-45.93%	84.96%	-1.81%
TOTAL LIABILITIES
Total Short-Term Liabilities	$378.2M	$54.25M	$105.4M
Total Long-Term Liabilities	$379.0K	$701.0K	$379.0K
Total Liabilities	$441.9M	$437.7M	$187.8M
YoY Change	-2.62%	133.12%	13.94%
SHAREHOLDERS EQUITY
Retained Earnings	-$645.0M	-$569.7M	-$599.3M
YoY Change	81.99%	-4.93%	61.31%
Common Stock	$1.548M	$1.545M	$1.524M
YoY Change	1.11%	1.38%	18.51%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$962.3M	$1.012B	$882.6M
YoY Change
Total Liabilities & Shareholders Equity	$1.404B	$1.450B	$1.070B
YoY Change	-12.47%	35.47%	77.5%

Cashflow Statement

Concept	2021 Q4	2021 Q3	2020 Q3
OPERATING ACTIVITIES
Net Income	-$75.26M	-$84.59M	-$58.23M
YoY Change	-130.73%	45.27%	25.87%
Depreciation, Depletion And Amortization	$2.094M	$2.187M	$2.100M
YoY Change	-0.29%	4.14%	10.53%
Cash From Operating Activities	-$65.49M	-$41.43M	$0.00
YoY Change	-112.74%		-100.0%
INVESTING ACTIVITIES
Capital Expenditures	-$3.053M	-$1.875M	-$700.0K
YoY Change	154.42%	167.86%	-75.0%
Acquisitions
YoY Change
Other Investing Activities	-$37.70M	-$51.13M	-$211.4M
YoY Change	-89.7%	-75.81%	-503.44%
Cash From Investing Activities	-$40.75M	-$53.01M	-$212.2M
YoY Change	-88.91%	-75.02%	-528.69%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	5.168M	3.315M	425.9M
YoY Change	-45.6%	-99.22%	60742.86%
NET CHANGE
Cash From Operating Activities	-65.49M	-41.43M	0.000
Cash From Investing Activities	-40.75M	-53.01M	-212.2M
Cash From Financing Activities	5.168M	3.315M	425.9M
Net Change In Cash	-101.1M	-91.13M	213.7M
YoY Change	-164.71%	-142.64%	979.29%
FREE CASH FLOW
Cash From Operating Activities	-$65.49M	-$41.43M	$0.00
Capital Expenditures	-$3.053M	-$1.875M	-$700.0K
Free Cash Flow	-$62.44M	-$39.56M	$700.0K
YoY Change	-112.12%	-5751.29%	-102.54%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	City Area Code CityAreaCode	650
	dei	Local Phone Number LocalPhoneNumber	866-8548
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Amendment Flag AmendmentFlag	false
	dei	Entity Central Index Key EntityCentralIndexKey	0001714899
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2021-09-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-38311
	dei	Entity Registrant Name EntityRegistrantName	Denali Therapeutics Inc.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	46-3872213
	dei	Entity Address Address Line1 EntityAddressAddressLine1	161 Oyster Point Blvd
	dei	Entity Address City Or Town EntityAddressCityOrTown	South San Francisco
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94080
	dei	Security12b Title Security12bTitle	Common Stock, par value $0.01 per share
	dei	Trading Symbol TradingSymbol	DNLI
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	false
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2021Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	122125581	shares
CY2021Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	394553000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	507144000	USD
CY2021Q3	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	644622000	USD
CY2020Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	962553000	USD
CY2021Q3	us-gaap	Due From Related Parties Current DueFromRelatedPartiesCurrent	1194000	USD
CY2020Q4	us-gaap	Due From Related Parties Current DueFromRelatedPartiesCurrent	5674000	USD
CY2021Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	15140000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	20284000	USD
CY2021Q3	us-gaap	Assets Current AssetsCurrent	1055509000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	1495655000	USD
CY2021Q3	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	319472000	USD
CY2020Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	32699000	USD
CY2021Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	40012000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	40846000	USD
CY2021Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	31196000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	32618000	USD
CY2021Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	3777000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2462000	USD
CY2021Q3	us-gaap	Assets Assets	1449966000	USD
CY2020Q4	us-gaap	Assets Assets	1604280000	USD
CY2021Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	4817000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1071000	USD
CY2021Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	10534000	USD
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	20503000	USD
CY2021Q3	dnli	Other Accrued Manufacturing Costs Current OtherAccruedManufacturingCostsCurrent	13142000	USD
CY2020Q4	dnli	Other Accrued Manufacturing Costs Current OtherAccruedManufacturingCostsCurrent	7140000	USD
CY2021Q3	dnli	Accrued Clinical And Other Research And Development Costs Current AccruedClinicalAndOtherResearchAndDevelopmentCostsCurrent	13380000	USD
CY2020Q4	dnli	Accrued Clinical And Other Research And Development Costs Current AccruedClinicalAndOtherResearchAndDevelopmentCostsCurrent	11775000	USD
CY2021Q3	dnli	Other Accrued Costs And Other Liabilities Current OtherAccruedCostsAndOtherLiabilitiesCurrent	2364000	USD
CY2020Q4	dnli	Other Accrued Costs And Other Liabilities Current OtherAccruedCostsAndOtherLiabilitiesCurrent	3037000	USD
CY2021Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	5252000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	4690000	USD
CY2021Q3	dnli	Contract With Customer Liability From Related Parties Current ContractWithCustomerLiabilityFromRelatedPartiesCurrent	3438000	USD
CY2020Q4	dnli	Contract With Customer Liability From Related Parties Current ContractWithCustomerLiabilityFromRelatedPartiesCurrent	3569000	USD
CY2021Q3	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	1324000	USD
CY2020Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	19914000	USD
CY2021Q3	us-gaap	Liabilities Current LiabilitiesCurrent	54251000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	71699000	USD
CY2021Q3	dnli	Contract With Customer Liability From Related Parties Noncurrent ContractWithCustomerLiabilityFromRelatedPartiesNoncurrent	291434000	USD
CY2020Q4	dnli	Contract With Customer Liability From Related Parties Noncurrent ContractWithCustomerLiabilityFromRelatedPartiesNoncurrent	293849000	USD
CY2021Q3	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	31313000	USD
CY2020Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	23325000	USD
CY2021Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	59990000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	64175000	USD
CY2021Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	701000	USD
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	701000	USD
CY2021Q3	us-gaap	Liabilities Liabilities	437689000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	453749000	USD
CY2021Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2021Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2021Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	40000000	shares
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	40000000	shares
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2021Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2021Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	400000000	shares
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	400000000	shares
CY2021Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	122011151	shares
CY2021Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	122011151	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	120531333	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	120531333	shares
CY2021Q3	us-gaap	Common Stock Value CommonStockValue	1545000	USD
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	1531000	USD
CY2021Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1580988000	USD
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1503660000	USD
CY2021Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-521000	USD
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-245000	USD
CY2021Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-569735000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-354415000	USD
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	1012277000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	1150531000	USD
CY2021Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1449966000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1604280000	USD
CY2021Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	5285000	USD
CY2020Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	9388000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	36143000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	18751000	USD
CY2021Q3	us-gaap	Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer	0	USD
CY2020Q3	us-gaap	Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer	5000	USD
	us-gaap	Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer	4000	USD
	us-gaap	Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer	93000	USD
CY2021Q3	us-gaap	Revenues Revenues	5285000	USD
CY2020Q3	us-gaap	Revenues Revenues	9393000	USD
	us-gaap	Revenues Revenues	36147000	USD
	us-gaap	Revenues Revenues	18844000	USD
CY2021Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	71559000	USD
CY2020Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	53704000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	197477000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	157872000	USD
CY2021Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	19319000	USD
CY2020Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	15805000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	57300000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	42332000	USD
CY2021Q3	us-gaap	Operating Expenses OperatingExpenses	90878000	USD
CY2020Q3	us-gaap	Operating Expenses OperatingExpenses	69509000	USD
	us-gaap	Operating Expenses OperatingExpenses	254777000	USD
	us-gaap	Operating Expenses OperatingExpenses	200204000	USD
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-85593000	USD
CY2020Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-60116000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-218630000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-181360000	USD
CY2021Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1005000	USD
CY2020Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1944000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	3310000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	7611000	USD
CY2021Q3	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-84588000	USD
CY2020Q3	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-58172000	USD
	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-215320000	USD
	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-173749000	USD
CY2021Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2020Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	56000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-84588000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-58228000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-215320000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-173749000	USD
CY2021Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax	-153000	USD
CY2020Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax	-540000	USD
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax	-276000	USD
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax	-339000	USD
CY2021Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-84741000	USD
CY2020Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-58768000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-215596000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-174088000	USD
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.69
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.69
CY2020Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.54
CY2020Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.54
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.77
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.77
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.65
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.65
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	121742067	shares
CY2021Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	121742067	shares
CY2020Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	107490702	shares
CY2020Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	107490702	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	121309197	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	121309197	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	105217770	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	105217770	shares
CY2021Q3	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	900000	USD
	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	2500000	USD
CY2021Q3	dnli	Research And Development Expense Offset From Related Party Cost Reimbursement ResearchAndDevelopmentExpenseOffsetFromRelatedPartyCostReimbursement	1200000	USD
	dnli	Research And Development Expense Offset From Related Party Cost Reimbursement ResearchAndDevelopmentExpenseOffsetFromRelatedPartyCostReimbursement	5300000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	1150531000	USD
	dnli	Stock Issued During Period Value Equity Incentive Plan StockIssuedDuringPeriodValueEquityIncentivePlan	14180000	USD
	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	0	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	63162000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-215320000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-276000	USD
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	1012277000	USD
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	1072705000	USD
CY2021Q3	dnli	Stock Issued During Period Value Equity Incentive Plan StockIssuedDuringPeriodValueEquityIncentivePlan	3315000	USD
CY2021Q3	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	0	USD
CY2021Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	20998000	USD
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-84588000	USD
CY2021Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-153000	USD
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	1012277000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	394890000	USD
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	193948000	USD
	dnli	Stock Issued During Period Value Stock Purchase Agreement StockIssuedDuringPeriodValueStockPurchaseAgreement	420146000	USD
	dnli	Stock Issued During Period Value Equity Incentive Plan StockIssuedDuringPeriodValueEquityIncentivePlan	11133000	USD
	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	0	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	36521000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-173749000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-339000	USD
CY2020Q3	us-gaap	Stockholders Equity StockholdersEquity	882550000	USD
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	502167000	USD
CY2020Q3	dnli	Stock Issued During Period Value Stock Purchase Agreement StockIssuedDuringPeriodValueStockPurchaseAgreement	420146000	USD
CY2020Q3	dnli	Stock Issued During Period Value Equity Incentive Plan StockIssuedDuringPeriodValueEquityIncentivePlan	5753000	USD
CY2020Q3	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	0	USD
CY2020Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	13252000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-58228000	USD
CY2020Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-540000	USD
CY2020Q3	us-gaap	Stockholders Equity StockholdersEquity	882550000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-215320000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-173749000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	6499000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	6410000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	63162000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	36521000	USD
	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	-6316000	USD
	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	1074000	USD
	dnli	Increase Decrease In Non Cash Operating Lease Expense IncreaseDecreaseInNonCashOperatingLeaseExpense	2201000	USD
	dnli	Increase Decrease In Non Cash Operating Lease Expense IncreaseDecreaseInNonCashOperatingLeaseExpense	1669000	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	0	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-18000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-8049000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-3819000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	3783000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	147000	USD
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-3036000	USD
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	4880000	USD
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-10601000	USD
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-17920000	USD
	dnli	Increase Decrease In Contract With Customer Liability Related Parties IncreaseDecreaseInContractWithCustomerLiabilityRelatedParties	-2546000	USD
	dnli	Increase Decrease In Contract With Customer Liability Related Parties IncreaseDecreaseInContractWithCustomerLiabilityRelatedParties	44854000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-145895000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-97763000	USD
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	1191491000	USD
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	687523000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	5447000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1900000	USD
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	1216062000	USD
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	433557000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	19124000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-255866000	USD
	dnli	Proceeds From Issuance Of Common Stock In Connection With Collaboration Agreement ProceedsFromIssuanceOfCommonStockInConnectionWithCollaborationAgreement	0	USD
	dnli	Proceeds From Issuance Of Common Stock In Connection With Collaboration Agreement ProceedsFromIssuanceOfCommonStockInConnectionWithCollaborationAgreement	420146000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	193948000	USD
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	14180000	USD
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	11133000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	14180000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	625227000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-112591000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	271598000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	508644000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	80949000	USD
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	396053000	USD
CY2020Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	352547000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	29000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	32000	USD
	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires the Company to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, as well as the reported amounts of expenses during the reporting period. Actual results could differ from those estimates, and such differences could be material to the Condensed Consolidated Balance Sheets and Statements of Operations and Comprehensive Loss.</span></div>
	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassifications</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain amounts in prior period financial statements have been reclassified to conform to the current period presentation. Such reclassifications have not materially affected previously reported amounts.</span></div>
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk and Other Risks and Uncertainties</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents, marketable securities and forward foreign currency exchange contracts. Substantially all of the Company’s cash and cash equivalents are deposited in accounts with financial institutions that management believes are of high credit quality. Such deposits have and will continue to exceed federally insured limits. The Company maintains its cash with accredited financial institutions and accordingly, such funds are subject to minimal credit risk. </span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s investment policy limits investments to certain types of securities issued by the U.S. government, its agencies and institutions with investment-grade credit ratings and places restrictions on maturities and concentration by type and issuer. The Company is exposed to credit risk in the event of a default by the financial institutions holding its cash, cash equivalents and marketable securities and issuers of marketable securities to the extent recorded on the Condensed Consolidated Balance Sheets. As of September 30, 2021 and December 31, 2020, the Company had no off balance sheet concentrations of credit risk. </span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is exposed to counterparty credit risk on all of its derivative financial instruments. The Company has established and maintains strict counterparty credit guidelines and enters into hedges only with financial institutions that are investment grade or better to minimize the Company’s exposure to potential defaults. The Company does not require collateral to be pledged under these agreements.</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to a number of risks similar to other early-stage biopharmaceutical companies, including, but not limited to, the need to obtain adequate additional funding, possible failure of current or future preclinical testing or clinical trials, its reliance on third parties to conduct its clinical trials, the need to obtain regulatory and marketing approvals for its product candidates, competitors developing new technological innovations, the need to successfully commercialize and gain market acceptance of the Company’s product candidates, its right to develop and commercialize its product candidates pursuant to the terms and conditions of the licenses granted to the Company, protection of proprietary technology, the ability to make milestone, royalty or other payments due under any license or collaboration agreements, and the need to secure and maintain adequate manufacturing arrangements with third parties. If the Company does not successfully commercialize or partner any of its product candidates, it will be unable to generate product revenue or achieve profitability.</span></div>The COVID-19 pandemic has caused increased risk and uncertainty for the Company. Credit risk associated with investments in securities may increase if any institution with which the Company has an investment is significantly impacted by the COVID-19 pandemic.
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	Segment
CY2021Q3	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	1500000	USD
CY2021Q3	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	1339895000	USD
CY2021Q3	us-gaap	Derivative Liabilities DerivativeLiabilities	201000	USD
CY2021Q3	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	201000	USD
CY2020Q4	us-gaap	Derivative Assets DerivativeAssets	185000	USD
CY2020Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	1480718000	USD
CY2020Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	11000	USD
CY2020Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	11000	USD
CY2021Q3	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	964265000	USD
CY2021Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	37000	USD
CY2021Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	208000	USD
CY2021Q3	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	964094000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	995147000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	130000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	25000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	995252000	USD
CY2020Q4	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0	USD
CY2021Q3	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0	USD
CY2021Q3	us-gaap	Debt Securities Available For Sale Term DebtSecuritiesAvailableForSaleTerm	P2Y
CY2021Q3	us-gaap	Revenues Revenues	5285000	USD
CY2020Q3	us-gaap	Revenues Revenues	9393000	USD
	us-gaap	Revenues Revenues	36147000	USD
	us-gaap	Revenues Revenues	18844000	USD
CY2021Q3	us-gaap	Lease Cost LeaseCost	2863000	USD
CY2020Q3	us-gaap	Lease Cost LeaseCost	2833000	USD
	us-gaap	Lease Cost LeaseCost	8429000	USD
	us-gaap	Lease Cost LeaseCost	8341000	USD
CY2021Q3	us-gaap	Operating Lease Payments OperatingLeasePayments	2618000	USD
CY2020Q3	us-gaap	Operating Lease Payments OperatingLeasePayments	2536000	USD
	us-gaap	Operating Lease Payments OperatingLeasePayments	7717000	USD
	us-gaap	Operating Lease Payments OperatingLeasePayments	7202000	USD
CY2021Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P7Y7M6D
CY2020Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P8Y7M6D
CY2021Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.09
CY2020Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.09
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	2618000	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	10702000	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	11053000	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	11417000	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	11793000	USD
CY2021Q3	dnli	Lessee Operating Lease Liability To Be Paid After Year Four LesseeOperatingLeaseLiabilityToBePaidAfterYearFour	42148000	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	89731000	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	24489000	USD
CY2021Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	65242000	USD
CY2021Q3	us-gaap	Sublease Income SubleaseIncome	1000000.0	USD
CY2020Q3	us-gaap	Sublease Income SubleaseIncome	900000	USD
	us-gaap	Sublease Income SubleaseIncome	2900000	USD
	us-gaap	Sublease Income SubleaseIncome	2800000	USD
CY2021Q3	us-gaap	Lessor Operating Lease Payments To Be Received Remainder Of Fiscal Year LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear	737000	USD
CY2021Q3	us-gaap	Lessor Operating Lease Payments To Be Received Next Twelve Months LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths	3009000	USD
CY2021Q3	us-gaap	Lessor Operating Lease Payments To Be Received Two Years LessorOperatingLeasePaymentsToBeReceivedTwoYears	3096000	USD
CY2021Q3	us-gaap	Lessor Operating Lease Payments To Be Received Three Years LessorOperatingLeasePaymentsToBeReceivedThreeYears	876000	USD
CY2021Q3	us-gaap	Lessor Operating Lease Payments To Be Received LessorOperatingLeasePaymentsToBeReceived	7718000	USD
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	12959926	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	16.31
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1944717	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	73.31
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	831207	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	14.27
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	259060	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	34.89
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	13814376	shares
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	24.11
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	12078689	shares
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	27.48
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	7856046	shares
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	15.22
CY2021Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	20998000	USD
CY2020Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	13252000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	63162000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	36521000	USD
CY2021Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	16498968	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	16498968	shares
CY2020Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	15950786	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	15950786	shares

Files In Submission

Name	View Source	Status
0001714899-21-000106-index-headers.html	Edgar Link	pending
0001714899-21-000106-index.html	Edgar Link	pending
0001714899-21-000106.txt	Edgar Link	pending
0001714899-21-000106-xbrl.zip	Edgar Link	pending
dnli-20210930.htm	Edgar Link	pending
dnli-20210930.xsd	Edgar Link	pending
dnli-20210930_cal.xml	Edgar Link	unprocessable
dnli-20210930_def.xml	Edgar Link	unprocessable
dnli-20210930_htm.xml	Edgar Link	completed
dnli-20210930_lab.xml	Edgar Link	unprocessable
dnli-20210930_pre.xml	Edgar Link	unprocessable
exhibit311q32021.htm	Edgar Link	pending
exhibit312q32021.htm	Edgar Link	pending
exhibit321q32021.htm	Edgar Link	pending
exhibit322q32021.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$DNLI
Denali Therapeutics Inc. Stock $dnli

2021 Q4 Form 10-Q Financial Statement

#000171489921000106 Filed on November 04, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$DNLI Denali Therapeutics Inc. Stock $dnli

2021 Q4 Form 10-Q Financial Statement

#000171489921000106 Filed on November 04, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$DNLI
Denali Therapeutics Inc. Stock $dnli